Renaissance Technologies - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 336 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2024$15,232,176
+227517.7%
222,400
+130.0%
0.03%
+136.4%
Q1 2024$6,692
-38.7%
96,700
-36.5%
0.01%
-35.3%
Q4 2023$10,915
-20.6%
152,400
-42.3%
0.02%
-26.1%
Q3 2023$13,752
-9.7%
264,000
+9.8%
0.02%
+4.5%
Q2 2023$15,228
-99.3%
240,500
+58.9%
0.02%
+1000.0%
Q1 2020$2,327,000
+117.9%
151,400
+84.0%
0.00%
+100.0%
Q2 2019$1,068,000
+4.5%
82,300
-1.9%
0.00%0.0%
Q1 2019$1,022,000
-35.8%
83,900
-40.0%
0.00%
-50.0%
Q4 2018$1,592,000
+58.1%
139,800
+201.3%
0.00%
+100.0%
Q3 2018$1,007,000
-94.2%
46,400
-94.7%
0.00%
-88.9%
Q2 2018$17,223,000
+50.1%
870,476
+59.7%
0.01%
-30.8%
Q1 2018$11,472,000
+37.7%
545,000
-5.3%
0.01%
+44.4%
Q4 2017$8,330,000
+31.5%
575,300
+43.3%
0.01%
+28.6%
Q3 2017$6,337,000
+103.6%
401,600
+60.3%
0.01%
+75.0%
Q2 2017$3,112,000
-30.6%
250,600
-9.2%
0.00%
-33.3%
Q1 2017$4,485,000
-31.0%
276,000
+18.0%
0.01%
-50.0%
Q1 2016$6,502,000
+170.5%
233,900
+423.3%
0.01%
+140.0%
Q4 2015$2,404,000
-67.2%
44,700
-75.6%
0.01%
-70.6%
Q3 2015$7,331,000
+613.8%
183,091
+325.8%
0.02%
+750.0%
Q1 2015$1,027,00043,0000.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2023
NameSharesValueWeighting ↓
DCF Advisers, LLC 375,000$15,308,0005.42%
SILVERARC CAPITAL MANAGEMENT, LLC 113,258$4,623,0002.06%
Tri Locum Partners LP 150,783$6,155,0002.02%
COOPER/HAIMS ADVISORS, LLC 61,116$2,495,0001.64%
Vantage Consulting Group Inc 226,670$9,252,0001.61%
Nicholas Investment Partners, LP 598,261$24,421,0001.53%
Bellevue Group AG 3,609,919$147,357,0001.44%
GENERAL AMERICAN INVESTORS CO INC 350,804$14,320,0001.20%
Rhenman & Partners Asset Management AB 429,728$17,541,0001.19%
WASATCH ADVISORS LP 6,506,789$265,607,0001.08%
View complete list of INTRA CELLULAR THERAPIES INC shareholders